Editorial expression of concern: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

Affiliations

¹ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Oncology, St. Vincent's University Hospital, Dublin 4, Ireland.
⁴ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. lodrisc@tcd.ie.

Editorial

Claire Corcoran et al. Mol Cancer. 2024.

. 2024 Oct 1;23(1):219.

doi: 10.1186/s12943-024-02139-z.

¹ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Department of Oncology, St. Vincent's University Hospital, Dublin 4, Ireland.
⁴ School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland. lodrisc@tcd.ie.

No abstract available

Expression of concern for

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer.
Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L. Corcoran C, et al. Mol Cancer. 2014 Mar 24;13:71. doi: 10.1186/1476-4598-13-71. Mol Cancer. 2014. PMID: 24655723 Free PMC article.